HCAP Summary

• Pneumonia

- It is an infection of the pulmonary parenchyma.
- It has two types:
 - 1- Community Acquired Pneumonia (CAP)

Acquired in the community. Caused by: Streptococcus Pneumoniae. It is usually susceptible (sensitive) to antibiotics.

2- Healthcare Associated Pneumonia (HCAP)

HCAP or Hospital Associated Pneumonia or nosocomial pneumonia.

Acquired 48-72 hours after admission to hospital.

Caused by Pseudomonas Aeruginosa, usually resistant to antibiotics.

• HAP or nosocomial pneumonia

- Second most common HAP, the First is urinary tract infection
- The incidence of nosocomial pneumonia is at its highest in the ICU
- There are two types of nosocomial pneumonia:
 - 1- Early onset nosocomial pneumonia:

Occurs during the first 4 days of admission. Usually due to Streptococcus Pneumoniae, MSSA, Haemophilus influenzae.

2- Late onset nosocomial pneumonia:

Occurs after more than 4 days of admission. Usually due to MRSA, or Gram negative organisms, especially(Pseudomonas

Aeruginosa, Acinetobacter, Enterobacteriaceae).

• Causative agents

- Enteric Gram negative bacilli (Enterobacteriaceae): Isolated particularly in patients with late onset disease and in patients with serious underlying disease who are often already on broad spectrum antibiotics. The of broadspectrum antibiotics, in addition to an immunocompromised state make Gram negative organisms more resistant.
- Pseudomonas Aeruginosaand Acinetobacter: Common causes of late onset pneumonia particularly in the ventilated patients.
- Staphylococcus Aureus: Isolated in about 20-40% of cases, common in:
 - 1) Ventilated patients after head trauma, neurosurgery, and wound infection.
 - 2) Patients who received prior antibiotics or prolonged care in ICU.
- MRSA:

Received corticosteroids.

Undergone mechanical ventilation >5 days.

Chronic lung disease (Like TB).

- Anaerobes : in patients predisposed to aspiration.

• VAP

- VAP is a nosocomial pneumonia that has developed in patient who are receiving mechanical ventilation.
- There are two types of VAP:
 - 1-Early onset: Within 48-72 hours after tracheal intubation.
 - 2- Late onset: After 72 hours.
- Pathogenesis

Requires two important processes:

- 1) Bacterial colonization of the aerodigestive tract.
- 2) Aspiration of contaminated secretion into the lower airway.
- Prevention with oral regimen (Topical Gentamicin, Colistin, or Vancomycin)

HAV and HAP

- Most initial therapy is empiric because no pathogen is identified or results are not yet available.
- First, we will treat with a broad spectrum antibiotic regimen to cover all likely bacterial pathogens, after that, the regimen.
- Guidelines by American Thoracic Societyhas divided HAP patients into three groups, each with a set of probable pathogens :

Group: Mild to moderate with no risk factor.

Group2: Mild to moderate with risk factor

Group3A: Severe, early onset with no risk factor.

Group3B: Severe, late onset or with risk factor.

The treatment for:

- Mild to moderate HAP: Monotherapy.
- Severe HAP with resistant organisms: Combination therapy.
- Patients with Staph. Aureusinfection: Vancomycin if MRSA is suspected. OR Linezolid which is less nephrotoxicity.
- Patients with Pseudomonas Aeruginosainfection: Combination of antipseudomonal drugs.
 - 1) Traditional approach: Antipseudomonal Betalactam+ Aminoglycoside . Synergy but potential nephrotoxicity.
 - 2) Another approach: Antipseudomonal Betalactam+ Fluoroquinolone. No benefit of synergy but reduces the concern of nephrotoxicity.

Response to therapy:

If no clinical response is noted or deterioration occurs, we need to consider the following :

- 1) Infectious causes: Resistant pathogen, Extrapulmonary infection, Lung abscess.
- 2) Non infectious events: is either related to heart or lung.